Explorez tous les épisodes du podcast NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In episode 172, “Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters,” Sandeep Rana, MD, a neurologist specializing in neuromuscular disorders at Allegheny Health Network, discussed the multidisciplinary care model for spinal muscular atrophy (SMA) implemented in his center, in honor of SMA Awareness Month. He described a clinic structure that includes physical and occupational therapists, respiratory therapists, nutritionists, speech therapists, social workers, and collaboration with pulmonologists experienced in neuromuscular disease.

Rana also outlined how the advent of disease-modifying therapies has transformed SMA from a largely fatal illness into a more manageable condition. He highlighted key advancements in therapeutics that have shifted priorities toward long-term wellness, including weight management, physical fitness, and emotional health. He noted persistent challenges in organizing and sustaining a specialized multidisciplinary team. Finally, he emphasized the importance of clinician awareness, early identification, and timely referral to tertiary centers, particularly as additional therapies may become available.

Looking for more neuromuscular disorder discussions? Check out the NeurologyLive® Neuromuscular Disorders clinical focus page.

Episode Breakdown:

• 1:25 – Professional background and clinic overview
• 2:55 – What an effective multidisciplinary SMA care team looks like
• 5:12 – How disease-modifying therapies have changed SMA care
• 6:28 – Neurology News Minute 
• 9:27 – Organizational and procedural challenges in coordinating care
• 11:52 – Why raising awareness about SMA is important & advice to clinicians
• 13:45 – Key message about SMA today 

The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date
• FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy
• FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this special edition of Mind Moments, Na Tosha Gatson, MD, PhD, senior medical director of neuro-oncology and director of the Center for Neuro-Oncology at Indiana University School of Medicine, joins the podcast to discuss her career journey, philosophy of patient care, and the launch of The G.L.O.B., a new recurring NeurologyLive column dedicated to advancing health literacy in neuro-oncology. Drawing on decades of experience in neuro-oncology, clinical leadership, and mentorship, Gatson shares the motivation behind creating a platform that transforms complex oncologic concepts into practical, accessible knowledge for clinicians, patients, and caregivers alike. 

The conversation explores the inspiration behind The G.L.O.B., the importance of effective medical communication, lessons learned throughout Gatson's career, and the role of health literacy, shared decision-making, and health equity in modern neurologic care. She also discusses her vision for the future of the column and why improving patient understanding should remain central to both clinical practice and research. 

Episode Breakdown:

• 1:10 – Journey into neuro-oncology and career-defining experiences
• 4:50 – Mission and philosophy behind The G.L.O.B.
• 7:10 – Key themes readers can expect from the column
• 9:45 – Career lessons that shaped Dr. Gatson's clinical practice
• 16:30 – Vision for The G.L.O.B. and improving healthy literacy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In episode 171, “Fragile X Syndrome Day: Clinical Challenges, Care Strategies, and Emerging Therapies,” Craig A. Erickson, MD, professor of psychiatry at Cincinnati Children’s Hospital, discussed the evolving landscape of Fragile X syndrome (FXS) care in honor of National Fragile X Syndrome Day. Erickson reviewed current challenges in recognizing and diagnosing FXS. He also underscored the importance of genetic testing and outlined key counseling points for families once a diagnosis is confirmed.

Erickson, who also serves as the director of the Cincinnati Fragile X Research and Treatment Center, provided an overview of behavioral and neuropsychiatric management across the lifespan. He highlighted evidence-informed approaches for ADHD, irritability and aggression, and anxiety, as well as the critical role of early intervention and structured supports in adulthood. The discussion closed with a look at emerging therapeutics and how these advances may reshape clinical practice and long-term outcomes for individuals with FXS.

Looking for more Genetic Disorders discussion? Check out the NeurologyLive® Genetic Disorders clinical focus page.

Episode Breakdown:

• 1:25 – Challenges in recognizing and diagnosing Fragile X 
• 3:25 – Genetic counseling and cascade testing after diagnosis 
• 6:00 – Managing behavioral and neuropsychiatric symptoms 
• 9:55 – News Minute 
• 12:45 – Clinical management across the lifespan 
• 17:12 – Emerging therapies and research priorities 
• 21:17 – Why Fragile X awareness remains critical 

The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
• FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea
• FDA Accepts NDA for Axsome Therapeutics’ AXS-12 for the Treatment of Cataplexy in Narcolepsy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Daniel Ontaneda, MD, PhD, professor of neurology at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses a recently published study in Neurology evaluating the application of the 2024 McDonald Criteria in individuals with nonspecific neurologic symptoms or incidental MRI findings. Using data from the CAHPS-MS study, Ontaneda explains how the revised diagnostic criteria perform in these previously understudied patient populations and what the findings may mean for earlier identification of multiple sclerosis. 

The conversation explores the rationale behind expanding the 2024 McDonald Criteria, the role of central vein sign and cerebrospinal fluid oligoclonal bands in improving diagnostic confidence, and how clinicians should approach patients who fall into a diagnostic gray zone. Ontaneda also discusses the practical application of the updated criteria, the importance of longitudinal follow-up, and how emerging biomarkers may continue to refine MS diagnosis in the years ahead.  

Looking for more Multiple sclerosis & demyelinating disorders discussion? Check out the NeurologyLive® Multiple sclerosis & demyelinating disorders clinical focus page.

Episode Breakdown:

• 1:15 – Why the 2024 McDonald Criteria expanded diagnostic eligibility
• 4:30 – Applying the criteria in nonspecific symptom presentations
• 6:20 – Clinical relevance of symptom patterns and MRI findings
• 8:40 – Using biomarkers to improve diagnostic confidence
• 11:25 – Neurology News Minute 
• 13:55– Interpreting dissemination in time with updated criteria
• 15:45 – Future validation of emerging MS diagnostic biomarkers

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Advisory Committee Schedules Meeting to Review Deramiocel's BLA in Duchenne Muscular Dystrophy
• FDA Clears PoNS Device for Stroke Rehabilitation, Expanding Neurostimulation Beyond MS Indication
• FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Grace Gombolay, MD, associate professor of pediatrics at Emory University School of Medicine and director of the Pediatric Neuroimmunology and Multiple Sclerosis Program at Children's Healthcare of Atlanta, joins Varun Kannan, MD, assistant professor of pediatrics in the Department of Neurology at Emory University School of Medicine and Children's Healthcare of Atlanta, for a discussion on acute disseminated encephalomyelitis (ADEM), a rare inflammatory demyelinating syndrome that remains an important diagnostic consideration in pediatric neuroimmunology. The conversation provides a practical overview of how clinicians should recognize ADEM, distinguish it from conditions such as multiple sclerosis, MOG antibody-associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD), and approach treatment in the absence of FDA-approved therapies. 

Gombolay and Kannan review the clinical and radiographic hallmarks of ADEM, the role of MRI and antibody testing in the diagnostic workup, and current treatment strategies involving corticosteroids, IVIG, and plasma exchange. They also discuss long-term outcomes, the evolving relationship between ADEM and MOGAD, emerging biomarkers such as neurofilament light chain and cytokine profiling, and common misconceptions that can complicate diagnosis and management in clinical practice. 

Looking for more Multiple sclerosis & demyelinating disorders discussion? Check out the NeurologyLive® Multiple sclerosis & demyelinating disorders clinical focus page.

Episode Breakdown:

• 1:15 – Recognizing the clinical and imaging features of ADEM
• 3:30 – Distinguishing ADEM from MS, MOGAD, and NMOSD
• 7:20 – Current treatment approaches and management strategies
• 10:10 – Neurology News Network 
• 12:40 – Long-term outcomes and monitoring after recovery
• 15:55 – Emerging biomarkers and improving diagnostic precision
• 19:10 – Preventing future attacks and reducing relapse risk
• 21:10 – Remaining research gaps and unanswered questions in ADEM

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Allows AMT-130 Huntington Disease Data to Support Planned BLA Submission Under Accelerated Approval Pathway
• Teva Submits NDA for Ecopipam, Potential First New Tourette Syndrome Treatment in Over a Decade
• FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory. 

The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development. 

Looking for more Headache & migraine discussion? Check out the NeurologyLive® Headache & migraine clinical focus page.

Episode Breakdown:

• 1:10 – PROCEED trial efficacy in patients with prior preventive failures
• 5:10 – Safety and tolerability findings for bocunebart
• 6:30 – Coadministration data with ubrogepant and clinical implications
• 8:30 – Neurology News Network 
• 10:50 – Rationale for combining PACAP and CGRP-targeted therapies
• 13:40 – Key considerations for future phase 3 development

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease
• FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention
• Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Todd Arnedt, PhD, professor of psychiatry and neurology at Michigan Medicine-University of Michigan, joins the podcast to discuss the recently published American Academy of Sleep Medicine clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Arnedt explains the rationale behind formal recommendations for concurrent use of cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, particularly as combination treatment becomes increasingly common in clinical practice. 

The conversation reviews the evidence supporting CBT-I as the preferred foundational treatment approach, where combination therapy may offer advantages over pharmacotherapy alone, and how clinicians should think about factors such as symptom burden, treatment goals, access to CBT-I, and patient preference when selecting treatment strategies. Arnedt also outlines ongoing research gaps involving sequential treatment approaches, medication classes, long-term outcomes, and personalized insomnia care. 

Looking for more Sleep Disorders discussion? Check out the NeurologyLive® Sleep Disorders clinical focus page.

Episode Breakdown:

• 1:15 – Why formal insomnia combination treatment guidance was needed
• 2:45 – Defining concurrent CBT-I and pharmacotherapy approaches
• 4:35 – Evidence supporting CBT-I as foundational insomnia treatment  
• 7:15 – Situations where combination therapy may improve patient outcomes
• 7:50 – Neurology News Network 
• 10:20 – Patient-specific factors influencing insomnia treatment selection
• 12:30 – Barriers involving CBT-I access, cost, and real-world implementation
• 16:55 – Research gaps surrounding sequencing, long-term outcomes, and personalization

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease
• FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention
• Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Scott Grossman, MD, assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine, discusses emerging research on inter-eye retinal nerve fiber layer (RNFL) asymmetry as a biomarker of prior optic neuritis in pediatric-onset multiple sclerosis (POMS). Drawing from data presented at the 2026 American Academy of Neurology Annual Meeting, Grossman explains how optical coherence tomography (OCT) may help improve diagnostic confidence in pediatric MS by identifying remote optic nerve injury, while also outlining how a 4-micron inter-eye RNFL difference emerged as the optimal threshold in this cohort. The conversation also explores the role of OCT within the updated 2024 McDonald Criteria, the feasibility of integrating OCT into routine neurology practice, challenges surrounding normative pediatric OCT data, and future research directions involving visible light OCT and broader population datasets. 

Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page.

Episode Breakdown:

• 1:15 – Optic nerve involvement and updated MS diagnostic criteria 
• 3:20 – Pediatric RNFL asymmetry thresholds and interpretation of study findings
• 5:15 – Clinical implications of OCT biomarkers in pediatric-onset MS 
• 6:40 – Neurology News Network 
• 8:40 – Feasibility of incorporating OCT into neurology and MS practice 
• 10:15 – Future research directions, including normative data and visible light OCT

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation
• FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
• Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Greg Pontone, MD, Chief of Aging Behavioral and Cognitive Neurology at the University of Florida, joins the podcast to discuss the interplay between cognition and Parkinson disease, with a focus on how clinicians can better recognize and manage cognitive changes across the disease course. Pontone outlines the prevalence of early cognitive impairment, noting that a significant proportion of patients may present with subtle deficits at diagnosis, particularly in executive function and processing speed. 

The conversation explores the impact of commonly used medications on cognition, including anticholinergics and benzodiazepines, and how clinicians can balance therapeutic benefit with cognitive risk. Pontone also reviews current treatment strategies, including cholinesterase inhibitors and memantine, while emphasizing the importance of nonpharmacologic approaches such as structured routines and cognitive training. Additional discussion highlights the evolving role of biomarkers, the overlap between Parkinson disease and Alzheimer pathology, and the need for earlier recognition, better patient education, and continued research to improve long-term cognitive outcomes in this population.

Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

Episode Breakdown:

• 1:10 – Prevalence and early signs of cognitive impairment in Parkinson disease 
• 2:30 – Medication-related cognitive effects and contributing drug classes
• 4:20 – Balancing therapeutic benefit vs cognitive risk in treatment decisions
• 6:05 – Current treatments for cognition, including pharmacologic and behavioral strategies
• 10:25 – Neurology News Network 
• 13:00 – Role of biomarkers and Alzheimer overlap in Parkinson cognition
• 15:45 – Future priorities for advancing cognitive care and research in PD

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor
• FDA Issues Complete Response Letter for GTx-104 in Patients With Aneurysmal Subarachnoid Hemorrhage
• Satralizumab Meets Primary End Point in Phase 3 METEOROID Study in MOGAD

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Julie Kurek, MD, Associate Professor of Neurology at Augusta University/Wellstar-MCG, joins the podcast to provide a clinical breakdown of how neurologists can differentiate dyskinesia from tremor in patients with Parkinson disease and other movement disorders. Drawing from bedside experience, Kurek outlines the key phenomenologic differences between these movements, emphasizing the importance of rhythm, distribution, and overall movement quality in distinguishing the two. 

The conversation also explores how timing in relation to levodopa dosing serves as a critical diagnostic anchor, including recognition of peak-dose and biphasic dyskinesias. Kurek discusses real-world challenges in identifying patient-specific patterns, the importance of clinician–patient communication, and common diagnostic pitfalls, particularly in younger-onset or atypical presentations. She also highlights the growing role of digital tools, including wearable sensors and adaptive deep brain stimulation, in improving longitudinal monitoring and refining diagnostic accuracy in movement disorders.

Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

Episode Breakdown:

• 1:10 – Clinical features distinguishing tremor vs dyskinesia at bedside 
• 3:50 – Role of medication timing and levodopa response patterns
• 9:00 – Identifying patient-specific patterns and symptom awareness challenges 
• 13:20 – Neurology News Network 
• 16:10 – Common diagnostic pitfalls in Parkinson disease and movement disorders
• 17:50 – Role of wearables, biomarkers, and adaptive DBS in differentiation

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts Ultragenyx's Resubmitted BLA for MPS IIIA Gene Therapy UX111
• Elecsys NfL Test Receives European Approval for Monitoring Neuroinflammation in Relapsing-Remitting Multiple Sclerosis
• FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Sarah Hoffmann, MD, PhD, senior neurologist at Charité – University Medicine Berlin, provides clinical insight into the evolving and often challenging landscape of seronegative generalized myasthenia gravis (gMG). Drawing from both clinical experience and research, Hoffmann discusses how seronegative MG is defined in the absence of detectable antibodies and why it represents a heterogeneous and often underrecognized subgroup of patients. The conversation explores key diagnostic challenges, particularly in patients with limb-predominant symptoms, where differentiation from other neuromuscular or functional disorders can be difficult. Hoffmann also reviews current treatment approaches, noting that while standard therapies mirror antibody-positive MG, access to targeted treatments remains limited. Additional discussion focuses on the barriers to advancing clinical trials in this population, the need for reliable biomarkers to better stratify patients, and the importance of continually reassessing diagnosis in nonresponders to avoid both undertreatment and overtreatment.

Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

• 1:15 – Defining seronegative MG and estimating prevalence within overall patient population 
• 2:15 – Diagnostic challenges and distinguishing seronegative MG from mimics and functional disorders 
• 5:35 – Role and limitations of antibody testing, electrophysiology, and pharmacologic response 
• 6:50 – Neurology News Network 
• 9:05 – Current treatment strategies and variability in access to targeted therapies 
• 11:55 – Barriers to clinical trials and need for improved patient stratification methods 
• 13:05 – Key unanswered questions including biomarkers and reassessing diagnosis in nonresponders 

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts Zilganersen New Drug Application for Priority Review in Alexander Disease
• FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome
• FDA Approves Higher Strength, More Effective Nusinersen Dose for Spinal Muscular Atrophy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, "Key Challenges Facing Neurology in the Year Ahead," Natalia Rost, MD, President of the American Academy of Neurology (AAN), Stroke Division Chief at Massachusetts General Hospital, and Professor of Neurology at Harvard Medical School, joins NeurologyLive to discuss the top clinical priorities shaping neurology in 2026.

Throughout the discussion, Rost outlines the most urgent unmet needs across neurology, including expanding equitable access to care, integrating preventive neurology into routine practice, strengthening the workforce, and closing persistent evidence gaps. She explains how the AAN Brain Health Initiative provides a practical framework for embedding brain health into everyday clinical encounters. The conversation also explores the growing role of biomarkers, imaging, and digital tools in care delivery, where innovation may be outpacing evidence, and how the Academy aims to guide ethical and evidence based implementation while addressing ongoing health equity gaps.

Episode Breakdown:

• 1:10 – Most urgent unmet clinical needs facing neurology in 2026
• 3:25 – Implementing brain health in everyday clinical practice
• 8:00 – Role of biomarkers, imaging, and digital tools in routine neurologic care
• 11:20 – AAN priorities for education, advocacy, and clinical guidance in 2026
• 14:25 – Major clinical gaps driving health inequities in neurologic care and outcomes

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Amaal Starling, MD, FAHS, FAAN, joins the podcast to provide clinical perspective on the INFUSE real world study evaluating IV eptinezumab in adults with migraine who previously found one or more CGRP preventive options ineffective, based on data presented at the 2026 Headache Cooperative of the Pacific Annual Conference. Starling, an associate professor of neurology at Mayo Clinic College of Medicine and a study author on INFUSE, discusses how clinicians should interpret the magnitude of benefit in a high burden population and why IV delivery, including rapid and consistent bioavailability, may help explain early and sustained response. The conversation also explores what the findings suggest for real world care and treatment sequencing, how migraine trials can better capture patient experience through outcomes like good days and PGIC, and what precision medicine research could look like next as the field pushes toward predictive modeling and individualized treatment selection.

Looking for more Headache & Migraine discussion? Check out the NeurologyLive® Headache & Migraine clinical focus page.

Episode Breakdown:

• 1:20 – Interpreting real world response after prior CGRP preventive failure
• 4:25 – Mechanistic reasons IV eptinezumab may drive early sustained benefit
• 6:25 – Clinical implications for earlier, more robust treatment sequencing
• 8:50 – Neurology News Network 
• 11:20 – Integrating good days and Patient Global Impression scales into migraine trial design
• 15:30 – Future studies needed to advance precision migraine care

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Fenebrutinib Achieves Primary End Point in Phase 3 Head-to-Head Trial vs Teriflunomide in Relapsing MS
• Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies
• Efgartigimod Meets Primary End Point in Phase 3 ADAPT OCULUS Study of Ocular Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this special Mind Moments episode, Lauren Sansing, MD, MS, FAHA, FANA, Professor of Neurology at Yale School of Medicine, joins the podcast to provide a clinical breakdown of the 2026 International Stroke Conference and its implications for real-world stroke care. Sansing reflects on how this year’s meeting built on prior advances, highlighting expanded global collaboration, greater patient engagement, and a record number of clinical trials presented. The discussion explores which late-breaking studies may influence practice in the coming year, including data on secondary stroke prevention, adjunctive thrombolysis strategies, and evolving patient selection for thrombectomy in extended windows and large core infarcts. Sansing also reviews renewed momentum in neuroprotection research, key updates from the newly released acute ischemic stroke guidelines, emerging pediatric stroke data, and how the conference continues to shape the roadmap for 2027 and beyond.

Looking for more Stroke discussion? Check out the NeurologyLive® Stroke clinical focus page.

Episode Breakdown:

• 1:00 – Biggest moments and structural evolution of ISC 2026
• 3:15 – Presented practice-changing trial data impacting stroke care
• 7:05 – Thrombectomy strategy and extended window patient selection
• 10:40 – Renewed momentum in neuroprotection research
• 15:20 – Neurology News Network 
• 17:40 – Key updates from the new acute ischemic stroke guidelines
• 25:00 – A brief look-ahead to ISC 2027

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• PTC Withdraws Ataluren Submission as Treatment for Nonsense Mutation Duchenne Muscular Dystrophy
• Microbiome-Targeted Agent PLL001 Passes Safety Check in Phase 1/2 Trial of ALS
• Rimegepant Displays Safety and Efficacy in Study of Adolescents With Migraine

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Jeff Chamberlain, PhD, joins the podcast during Duchenne Muscular Dystrophy Awareness Week to provide clinical and translational perspective on the evolving landscape of DMD biology and therapy. Chamberlain, professor at the University of Washington School of Medicine and Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center in Seattle, reflects on aspects of Duchenne pathophysiology that may still be underappreciated, including evidence that disease processes begin earlier than once recognized and the growing importance of immunologic factors in shaping progression and therapeutic response. The conversation also explores how neuromuscular specialists should approach treatment timing and combination strategies as gene-targeted therapies expand, the evolving interpretation and limitations of biomarkers such as creatine kinase and dystrophin expression, and what emerging gene therapy platforms may signal for care heading into 2026 and beyond.

Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

• 1:15 – Underrecognized aspects of DMD pathophysiology, including early onset and immunologic drivers
• 4:50 – Treatment timing, sequencing, and the rationale for combination strategies
• 8:00 – Neurology News Minute
• 10:30 – Clinical trial and real-world implications of dystrophin and CK as biomarkers
• 16:20 – Anticipated gene therapy innovation and safety considerations heading into 2026

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL
• FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review
• FDA Expands Indication for Pitolisant to Treat Cataplexy in Pediatric Narcolepsy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this special edition of Mind Moments, Shyam Prabhakaran, MD, MS, the James Nelson and Anna Louise Raymond Professor of Neurology and chair of the Department of Neurology at the University of Chicago Medicine, joined the show to discuss the recent updates to the American Heart Association/American Stroke Association's guideline for the early management of acute ischemic stroke.  Prabhakaran clarified the main takeaways for clinicians and touched on details around endovascular thrombectomy care in pediatrics as well as treatment within and outside of the golden window.

For NeurologyLive's coverage of ISC 2026, head here: International Stroke Conference (ISC)

To read the new guidelines, head here: 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Benjamin Tolchin, MD, MS, FAAN, joins the podcast to provide clinical perspective on the recently published American Academy of Neurology (AAN) guidelines on functional seizures, drawing on his role as a contributing author to the recommendations. Tolchin, Director of the Center for Clinical Ethics at Yale New Haven Health and Associate Professor of Neurology at Yale School of Medicine, discusses what prompted the development of the first AAN guideline in this space and how the evidence base evolved to support formal recommendations. The conversation explores key considerations around diagnosing functional seizures, including history, semiology, EEG use, and the growing role of video documentation. Tolchin also addresses how clinicians should approach psychiatric comorbidities and co-occurring epilepsy, the evidence supporting psychological interventions, why pharmacologic therapies are not recommended for functional seizures themselves, and where major gaps remain in research to advance care in the years ahead.

Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:10 – Why growing evidence prompted the first AAN guideline on functional seizures
• 3:20 – Diagnostic priorities including history, semiology, EEG, and video documentation
• 6:15 – Assessing psychiatric comorbidities and co-occurring epilepsy in functional seizures
• 9:15 – Neurology News Minute
• 11:30 – Evidence supporting psychotherapy for functional seizures
• 14:50 – Pharmacological evidence and use of antiseizure medications for functional seizures
• 18:35 – Barriers to advancing clinical trials in functional seizures
• 22:05 – Research priorities to refine treatment and long-term outcomes

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease
• sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis
• High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies," Johannes Streffer, MD, PhD, discusses phase 1/2 findings from the PACIFIC trial evaluating bexicaserin in developmental epileptic encephalopathies, presented at the American Epilepsy Society 2025 Annual Meeting. Streffer, senior vice president of clinical development at Lundbeck, outlines the scientific and clinical rationale for studying DEEs as a unified population, emphasizing the unmet need and complexity of trial design in this highly vulnerable group. He reviews key efficacy outcomes, including sustained reductions in countable motor seizures and strong patient retention through long-term open-label extension and expanded access follow-up. The discussion also explores safety and tolerability considerations in patients receiving multiple concomitant antiseizure medications, the highly selective mechanism of action of bexicaserin, and how Lundbeck’s broader strategy in rare neurological disorders aims to de-risk development early while addressing populations with limited therapeutic options.

Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:05 – Rationale for studying developmental epileptic encephalopathies as a unified group
• 3:05 – Challenges of trial design and retention in vulnerable pediatric DEE populations
• 5:25 – Key PACIFIC efficacy findings and long-term open-label extension results
• 7:05 – Neurology News Minute
• 9:15 – Safety, tolerability, and drug-drug interaction considerations for bexicaserin
• 11:20 – Lundbeck's strategy across rare and severe neurological disorders

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis
• Semaglutide Linked to Improved Neurological Outcomes in Large Vessel Occlusion Without IV Thrombolysis
• FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Clinical Advances and Unanswered Questions in Narcolepsy," Lindsay McCullough, MD, discusses how clinical understanding of narcolepsy has evolved, where major diagnostic and treatment advances have occurred, and where important gaps remain. McCullough, assistant professor of medicine and associate program director for the sleep medicine fellowship at Rush University, reflects on progress in defining narcolepsy subtypes, the growing role of orexin biology, and how recent research in 2025 has reshaped conversations around disease-modifying approaches. The discussion also explores emerging links between sleep disorders and neurodegenerative disease, common misconceptions that continue to delay diagnosis, and how clinician education can improve recognition, safety, and long-term management of patients with narcolepsy.

Looking for more Sleep Disorder discussion? Check out the NeurologyLive® Sleep Disorder clinical focus page.

Episode Breakdown:

• 1:05 – Advances and remaining gaps in the clinical understanding of narcolepsy
• 2:30 – How narcolepsy care and research meaningfully evolved throughout 2025
• 4:50 – Sleep disorders, neurodegeneration, and what clinicians should watch for
• 6:50 – Neurology News Minute
• 8:50 – Persistent myths that delay diagnosis and affect clinical decision-making
• 12:30 – How lived experience shapes holistic, patient-centered narcolepsy care

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis
• FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS
• Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Mood, Behavior, and Quality of Life in Parkinson Disease," Sneha Mantri, MD, MS, Chief Medical Officer at the Parkinson’s Foundation, discusses how mood and behavioral symptoms shape the lived experience of people with Parkinson disease across the disease course. Mantri, a practicing movement disorders specialist with extensive training and experience, explains why depression and anxiety often precede motor symptoms, how these issues evolve with cognitive change, and why they remain key drivers of quality of life. Mantri reviews commonly used screening tools – including the PHQ-2/9, Geriatric Depression Scale, GAD-7, and emerging measures like the HOPE questionnaire – emphasizing their role in opening deeper clinical conversations. She also highlights Parkinson’s Foundation initiatives that support both clinicians and patients, from PD Health at Home programming to team-based care models. The conversation concludes with ongoing challenges, including cultural barriers to mental health care, access limitations, and the continued need for true mental health parity in Parkinson disease management.

Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

Episode Breakdown:

• 1:10 – How mood and behavior symptoms shape Parkinson disease quality of life
• 5:30 – How conversations about mental health in Parkinson disease have evolved
• 9:25 – Screening tools and practical assessment strategies for mood and anxiety
• 13:40 – Neurology News Minute
• 15:50 – Foundation and community initiatives supporting mood and behavior care
• 19:50 – Remaining gaps, cultural barriers, and mental health parity challenges

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
• Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program
• FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Understanding Variability in Infantile Spasms Care," Christina Briscoe, MD, epileptologist at Boston Children’s Hospital, discusses new multi-center findings on current treatment practices for infantile epileptic spasms syndrome (IESS). Briscoe outlines why first- and second-line therapies remain largely standardized, yet significant variability emerges once hormonal therapy and vigabatrin fail. She details the evidence gaps driving inconsistent third-line and fourth-line decision-making, including limited clinical trial data, uneven access to ketogenic diet programs and epilepsy surgery, and historically low industry investment in infant-specific trials. Additional discussion focuses on ongoing research from the Pediatric Epilepsy Research Consortium, national and global comparisons in treatment pathways, barriers to study scalability in rare pediatric epilepsies, and the practical challenges of implementing timely diagnosis and standardized care across diverse healthcare settings. Briscoe also highlights under-recognized issues such as incorporation of ketogenic diet and early surgical evaluation into treatment pathways, and emphasizes the need for broader infrastructure, funding, and multi-center collaboration to improve outcomes for children with IESS.

Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:05 – Origins of the study, need to pursue more standardized care in IESS
• 4:40 – Reasons behind treatment variability after first and second-line options
• 8:00 – What research is needed to guide sequencing and standardize care
• 12:05 – Neurology News Minute
• 14:30 – What makes IESS studies difficult and how infrastructure can improve
• 18:50 – Lesser-discussed gaps, including ketogenic diet and surgical evaluation

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission
• FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy
• GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "NEALS 2025: Takeaways That Matter for ALS Care," ALS experts Jinsy Andrews, MD, MSc, and James Berry, MD, MPH, reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for ALS. They discuss format changes that elevated lightning science, the expanding gene therapy pipeline, and a growing slate of NEALS-affiliated trials. The conversation highlights updates from the HEALEY Platform Trial, the MY-MATCH biomarker-guided precision trial, SOD1 program data, and new antisense and viral vector therapies aimed at sporadic ALS. They also explore the impact of Act for ALS on trial access, the ALL ALS biospecimen repository, and NIH-supported expanded access cohorts. The discussion closes with insights on combination therapy strategies, genetic subtypes, presymptomatic enrollment, and how new collaborations, digital endpoints, and infrastructure advances are shaping momentum heading into 2026.

Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

• 1:05 – Reflections on meeting highlights and NEALS rebranding into a global network
• 5:00 – Notable NEALS-affiliated trials and promising new mechanisms in ALS care
• 12:45 – Combination therapy strategies and future approaches in ALS research
• 15:20 – Neurology News Minute
• 18:00 – Expanding clinical trial access for rare and genetic ALS subtypes
• 22:10 – Building momentum and expectations for the 2026 NEALS Annual Meeting

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
• Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation
• BTK Inhibitor Fenebrutinib Meets Primary End Points in Phase 3 Trials for Both Relapsing and Primary Progressive MS 

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

Following the 2025 Alzheimer's Association International Conference (AAIC), Rebecca Edelmayer, PhD, outlines the Alzheimer’s Association’s first clinical practice guidelines for using blood-based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer’s disease within specialized care. She explains the guideline mission, how tests were evaluated for accuracy, and when BBMs should serve as triage versus confirmatory tools relative to CSF and PET. Edelmayer details current scope limits (cognitively impaired patients in specialty settings), cautions against overextending to primary care or unimpaired populations, and previews the education roll-out—executive summaries, micro-learning modules, and shared decision-making resources. She closes with research priorities: stronger peer-reviewed reporting, broader validation across diverse populations and settings, and building an equitable pathway that leverages BBMs to speed accurate diagnosis and treatment access.

Looking for more Alzheimer & dementia discussion? Check out the NeurologyLive® Alzheimer & dementia clinical focus page.

Episode Breakdown:

• 1:05 – Understanding the purpose and mission behind new blood-based biomarker guidelines
• 2:05 – Key recommendations and defining triage vs confirmatory blood-based biomarker use
• 3:15 – Clinical precautions and where blood-based biomarkers are appropriate today
• 5:30 – Neurology News Minute
• 7:45 – Educating clinicians on implementing BBMs in specialty care
• 10:15 – Research priorities to strengthen evidence and ensure equity

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease
• B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial
• Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Building Safer, Smarter, and More Personalized Epilepsy Care," Orrin Devinsky, MD, discusses major areas of progress and ongoing challenges in epilepsy care. Devinsky, a professor in the departments of neurology, neurosurgery, and psychiatry at NYU Grossman School of Medicine, reflects on how the treatment landscape has evolved in recent years, including advances in medication, awareness of SUDEP, and patient counseling. Devinsky also weighs in on the current treatment hierarchy for antiepileptic drugs and whether first-line therapeutic strategies should change. Additional discussion touches on the state of gene therapy development, the need for greater research in disease prevention, the implications of GLP/GIP agents in neurological care, and how neurodevelopmental management is advancing for pediatric patients with epilepsy.

Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 0:55 – How epilepsy care has evolved and where progress has been made
• 5:30 – Whether first-line therapy choices for epilepsy should be re-evaluated
• 8:35 – Why gene therapy progress has been slower than expected in epilepsy
• 12:05 – Neurology News Minute
• 14:10 – What areas of epilepsy research deserve greater attention and funding
• 17:10 – How GLP/GIP agents could intersect with neurological and epilepsy care
• 20:00 – How clinicians can better address neurodevelopmental challenges in patients with epilepsy

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Neflamapimod Advances to Phase 3 Trial in Dementia With Lewy Bodies After Positive RewinD-LB Results
• FDA Delays Review Deadline for Hunter Syndrome Agent Tividenofusp Alfa
• FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "ECTRIMS 2025 Meeting Highlights and Clinical Takeaways," Daniel Ontaneda, MD, PhD, neurologist at Cleveland Clinic’s Mellen Center for MS, shared his reflections from the 2025 ECTRIMS Congress, held September 24-26, in Barcelona, Spain. He discussed the significance of the updated MS diagnostic criteria, which generated immediate research applications and clinician discussion early in the meeting. Ontaneda also highlighted the growing emphasis on precision medicine and individualized treatment approaches, including extended-interval dosing strategies for B-cell therapies. In addition, he reviewed new therapeutic developments such as BTK inhibitors, CAR-T therapies, and remyelination research, noting both promising and disappointing data. Finally, he spoke on how ECTRIMS continues to expand beyond MS, with more presentations dedicated to NMOSD, MOGAD, and other autoimmune neurological conditions, reflecting the evolving landscape of neuroimmunology.


Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page.

Episode Breakdown:

• 1:00 – Overall impressions of ECTRIMS 2025, highlighting diagnostic updates, precision medicine, and late-breaking trial results
• 4:10 – Expanding focus on individualized care, especially interval-adjusted dosing strategies for B-cell therapies
• 7:50 – Neurology News Minute
• 9:50 – Insights on emerging therapeutic approaches including BTK inhibitors, CAR-T therapies, and remyelination strategies
• 14:35 – Growing attention toward NMOSD, MOGAD, and other autoimmune conditions within neuroimmunology discussions

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
• Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
• MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Rethinking Parkinson’s Care: Prevention, Equity, and Access to Treatment," Michael Okun, MD, neurologist, author of The Parkinson Plan, and medical advisor for the Parkinson’s Foundation, discusses the urgent need for global access to levodopa, the gold-standard treatment for Parkinson disease. He outlines the consequences of delayed or unavailable treatment worldwide, including worsening outcomes and unnecessary disability. Okun highlights lessons from global HIV drug distribution that can inform equitable levodopa access, emphasizing the importance of tailoring strategies to local economies and healthcare systems. Additionally, he breaks down key components of The Parkinson Plan, including prevention, research priorities, amplifying patient and caregiver voices, and rethinking care models to better address the world’s fastest growing neurodegenerative disorder. Finally, he explains how the book can serve as a resource not only for clinicians, but also for patients, families, and policymakers.


Looking for more Movement disorders discussion? Check out the NeurologyLive® Movement disorders clinical focus page.

Episode Breakdown:

• 1:00 – Consequences of delayed or unavailable levodopa treatment for patients worldwide
• 2:40 – How universal levodopa access could change care in low-resource settings
• 5:15 – Lessons from global HIV drug distribution for equitable levodopa delivery
• 7:00 – Neurology News Network
• 8:35 – Key pillars of The Parkinson Plan and rethinking Parkinson’s care models

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
• Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
• MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this special edition of Mind Moments, Patricia Pozo-Rosich, MD, PhD, head of the neurology department at Vall d’Hebron University Hospital, discussed the recent FDA approval of fremanezumab (Ajovy) for pediatric migraine prevention. As a study author on the pivotal phase 3 SPACE trial (NCT03539393), Dr. Pozo-Rosich reflected on the significance of having a proven therapeutic option in a population where placebo responses and lack of evidence have long complicated care. She provided insights on how the trial was designed and the challenges of running pediatric studies, particularly in adolescents. Additionally, she highlighted broader implications for migraine research, including efforts to reduce placebo effects, the role of CGRP pathway inhibition in younger patients, and the future promise of emerging targets such as PACAP antagonists and new toxin formulations.


For more of NeurologyLive's coverage of fremanezumab's expanded indication in pediatric migraine, head here: FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine
Episode Breakdown:

• 1:10 – Initial reaction to fremanezumab approval and significant for pediatric migraine care
• 6:05 – Major clinical insights and takeaways from phase 3 SPACE trial
• 10:20 – Challenges in pediatric migraine trials and addressing high placebo responses
• 15:10 – Future directions in migraine therapy, including PACAP-targeting drugs and novel approaches

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne," Barry Byrne, MD, chief medical advisor at the Muscular Dystrophy Association and director of the Powell Gene Therapy Center at the University of Florida, discusses newly published consensus guidelines from the MDA and Parent Project Muscular Dystrophy on the safe delivery and monitoring of gene therapy in Duchenne muscular dystrophy (DMD). Byrne explains the rationale behind convening a global panel of experts, emphasizing the need for standardized practices in patient selection, administration, and follow-up care as gene therapy becomes more widely available. He highlights the importance of expanded multidisciplinary teams—including hematology, cardiology, nephrology, and immunology—in managing immune-related safety concerns, with particular attention to monitoring liver inflammation and emerging strategies such as rapamycin use. In addition, Byrne outlines how these guidelines address real-world challenges around access, including geographic barriers, language considerations, and financial constraints, while underscoring their role in shaping future gene therapy approaches as additional therapies move through development.


Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

• 1:00 – Why consensus guidelines were needed for gene therapy in DMD
• 2:10 – Top-line clinical considerations from the published recommendations
• 4:30 – Protocols for monitoring and managing adverse events, especially liver toxicity
• 6:30 – Neurology News Network
• 8:30 – Addressing health equity, language access, and financial barriers in gene therapy care
• 12:00 – How these recommendations may shape the future of DMD treatment
  
  

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data
• FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease
• Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care," Danielle Andrade, MD, MSc, adult neurologist at the University of Toronto and co-chair of the ILAE Transition Task Force, discussed the critical process of moving pediatric patients with epilepsy into adult care. She highlighted findings from the task force’s global survey on transition practices, revealing major differences across regions. Andrade also shared important considerations for students with epilepsy entering college, including lifestyle management and the “perfect storm” of seizure triggers like sleep deprivation, alcohol, and medication adherence. She spoke on the vital role of reproductive health discussions, the utility of readiness questionnaires, and the challenges of coordinating multi-specialty care. Finally, Andrade underscored the importance of clear communication between pediatric and adult neurologists, as well as the need for stronger guidelines and education worldwide.


Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:00 – Global survey findings on epilepsy transition of care
• 2:10 – Key considerations for students with epilepsy entering college
• 3:50 – Ensuring continuity of care during transition into adulthood
• 5:45 – Neurology News Minute
• 7:30 – Common challenges and strategies to overcome them
• 9:30 – Final thoughts on back-to-school care and global survey insights

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease
• Praxis’ Vormatrigine Shows Significant Ability to Reduce Seizure Incidence in Phase 2 RADIANT Study
• FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management" Alex Dessy, MD, clinical assistant professor in movement disorders at Jefferson Health, shares a comprehensive look at modern-day care strategies for patients with Parkinson disease and other movement disorders. Dessy discusses the foundational role of detailed history-taking, exam-based observation, and phenomenology in diagnosing complex conditions, along with the growing utility of genetic and imaging tools. She also explains the challenges of managing nonmotor symptoms—like sleep disturbance, fatigue, and constipation—and how lifestyle strategies and interdisciplinary collaboration are often as vital as medication. Lastly, she emphasizes the importance of clear and compassionate communication with patients and families as neurology becomes increasingly therapeutic.


Looking for more Movement disorders discussion? Check out the NeurologyLive® Movement disorders clinical focus page.

Episode Breakdown:

• 1:00 – How movement disorder diagnosis is approached through history, physical exam, and phenomenology
• 4:05 – What makes certain movement disorder cases complex and how diagnostics like genetics and imaging are used
• 6:20 – Neurology News Minute
• 8:45 – How nonmotor symptoms in Parkinson’s (fatigue, constipation, sleep) are managed with lifestyle strategies
• 12:30 – Approaching therapeutic communication and expectation-setting with patients and families

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Eisai Showcases Promising 4-Year Data for Alzheimer Therapy Lecanemab at AAIC 2025
• IHL-42X to Enter Phase 3 Trials for Obstructive Sleep Apnea Following Positive Phase 2 Data
• FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer’s Care" John Sims, MD, head of medical development for donanemab at Eli Lilly and Company, joins NeurologyLive to discuss the recently updated label for donanemab (Kisulna), an anti-amyloid Alzheimer disease (AD) therapy. Sims breaks down the key safety data from the TRAILBLAZER-ALZ-6 study (NCT05738486) that led to a newly approved titration-based dosing regimen aimed at minimizing ARIA risk. He outlines considerations for clinicians treating patients with early-stage AD, including genotype-based stratification, ARIA severity patterns, and implications for prescribing and patient counseling. Furthermore, Sims also shares takeaways about donanemab’s clinical impact and how the results may shape the future of anti-amyloid therapy development and AD care.

Looking for more dementia and Alzheimer disease discussion? Check out the NeurologyLive® Dementia and Alzheimer disease clinical focus page.

Episode Breakdown:

• 1:00 – Overview of the new donanemab dosing regimen and its goal to reduce ARIA risk
• 2:30 – Rationale behind the four different dosing strategies tested in Trailblazer-ALZ-6
• 6:00 – What clinicians should know about patient risk and genotype testing
• 8:00 – Neurology News Minute
• 10:10 – Clinical implications of the updated label, including risk-benefit conversations
• 13:45 – Surprising results from the trial, particularly for APOE4 homozygous patients
  
  

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies
• FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths
• AD109 Meets End Points in Phase 3 LunAIRo Trial, Eyeing FDA Submission for Obstructive Sleep Apnea

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this special FDA-focused episode of Mind Moments, migraine expert Stewart Tepper, MD, professor of neurology at the Geisel School of Medicine at Dartmouth, discusses the recent FDA approvals of STS101 (Atzumi; Satsuma Pharmaceuticals) and CT-132 ( ) for the acute and preventive treatment of migraine. Tepper breaks down the pharmacological profile and clinical utility of DHE, the formulation behind STS101, and how the latest delivery innovations may expand its use in acute migraine care. He also dives into the approval data behind CT-132, the first-ever FDA-approved prescription digital therapeutic for migraine, and what it could mean for patients and clinicians alike. Tepper highlights the need for clinician education as novel therapeutics reshape the treatment landscape and offers insight into how these new tools could improve patient outcomes with fewer side effects and better accessibility.


For more of NeurologyLive's coverage of STS101 and CT-132 for migraine, head here: FDA Approves STS101 Nasal Powder as New Treatment for Acute Migraine FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine
Episode Breakdown:

• 1:10 – Overview of DHE, patient suitability, and STS101’s place in treatment
• 6:05 – Efficacy and safety data from the ASCEND and SUMMIT trials for STS101
• 10:20 – The expanding migraine toolbox and need for clinician education
• 15:10 – CT-132’s first-in-class status and clinical trial data
• 16:25 – Clinical use of CT-132 as an add-on preventive
• 19:30 – The knowledge gap on digital therapeutics and educating the neurology community
• 23:00 – Future directions and hopes for expanded CT-132 research

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joyce Lee-Iannotti, MD, PhD, division chief of both the Stroke Center and the Comprehensive Sleep Center at Barrow Neurological Institute, discusses her presentation from the 2025 SLEEP Annual Meeting focused on the glymphatic system’s role in stroke. She outlines the science behind this brain-cleansing pathway, its dependence on sleep quality, and how its dysfunction may worsen outcomes in both ischemic and hemorrhagic stroke. Lee-Iannotti also details practical, evidence-backed strategies for optimizing glymphatic clearance—from sleep posture and sleep apnea treatment to emerging pharmacologic options like orexin antagonists. In addition, she highlights major gaps in clinician awareness and offers calls to action for improving sleep assessments in stroke care.

Looking for more Sleep disorders discussion? Check out the NeurologyLive® Sleep disorders clinical focus page.

Episode Breakdown:

• 1:00 – Overview of the glymphatic system and its relevance in stroke care
• 2:55 – Evidence linking sleep quality and glymphatic activity in stroke prevention and recovery
• 7:40 – Neurology News Minute
• 10:05 – Potential interventions: pharmacologic and nonpharmacologic approaches to enhance glymphatic function
• 13:10 – Raising clinical awareness of sleep’s role in stroke and neurologic disease management
  
  

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Grants Priority Review, Sets PDUFA Date for Hunter Syndrome Treatment Tividenofusp Alfa
• FDA Approves Updated Label for Alzheimer Therapy Donanemab to Lower ARIA-E Risk
• Exablate Neuro Gains FDA Approval for Staged Bilateral Focused Ultrasound in Advanced Parkinson Disease

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joseph Sullivan, MD, director of the Pediatric Epilepsy Center at UCSF, joins Mind Moments to discuss the clinical distinctions between Dravet syndrome and Lennox-Gastaut syndrome (LGS). Sullivan outlines the unique diagnostic profiles, seizure presentations, and genetic underpinnings of each disorder, while also addressing how genetic testing has transformed the approach to Dravet syndrome in particular. He speaks on the future of targeted therapies, highlighting ongoing research in disease-modifying treatments and n-of-1 trials, especially for ultra-rare epilepsies. Additionally, Sullivan explores how the clinical trial landscape is evolving—emphasizing the need for biomarkers, innovative trial design, and better tools for seizure monitoring to improve outcomes in these complex pediatric epilepsies.

Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:00 – Key differences in phenotype and diagnosis between Dravet syndrome and LGS
• 3:00– The evolution of genetic testing and how it’s improved Dravet diagnosis and outcomes
• 5:25 – Opportunities and limitations in scaling genetic testing more broadly
• 6:35 – Neurology News Minute
• 8:45 – Research pipelines: disease-modifying therapies, n-of-1 trials, and future directions
• 10:20 – Innovations in clinical trial design and the need for better seizure monitoring and biomarkers

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP
• FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis
• Grace Therapeutics Submits NDA for GTX-104 to Treat Aneurysmal Subarachnoid Hemorrhage

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease" Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center, discusses the phase 3 exPDite-2 trial evaluating bemdaneprocel, an investigational cell therapy for Parkinson disease (PD). Pahwa explains the rationale behind cell replacement therapy as a means to restore dopamine production, outlining the progression from fetal tissue implants to stem cell–derived dopaminergic neurons. He details key elements of the study design, including patient selection criteria, trial endpoints, and long-term goals. Reflecting on decades of research in this space, he emphasizes the potential impact of a one-time, hardware-free surgical option and how this novel approach could complement or shift the current treatment landscape. While many questions remain, Pahwa highlights the promise of bemdaneprocel as a next-generation option in Parkinson care.

Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

Episode Breakdown:

• 1:00 – Mechanism and rationale behind bemdaneprocel as a dopaminergic cell therapy
• 3:00– Key design considerations for conducting a registrational phase 3 cell therapy trial
• 5:25 – Trial structure, eligibility criteria, and ongoing patient recruitment
• 6:35 – Neurology News Minute
• 8:45 – Significance of reaching phase 3 with a cell therapy in Parkinson disease
• 10:20 – Future role of cell therapy within the Parkinson disease treatment landscape
• 12:10 – Unique aspects of the exPDite-2 trial and what sets it apart from earlier efforts

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• BTK Inhibitor Fenebrutinib Demonstrates Long-Term Suppression of MS Activity in Open-Label Extension
• REGENXBIO Reports Positive Phase 1/2 Data for Higher Dose of RGX-202 in Duchenne Muscular Dystrophy
• NewAmsterdam Pharma Reports Positive Topline Data of Alzheimer Agent Obicetrapib from Phase 3 BROADWAY Trial

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "World MS Day: Raising Awareness, Evolving Care, and Empowering Patients," Taylor Hess, MD, a multiple sclerosis specialist at the Michigan Institute for Neurological Disorders (MIND), shares insights in recognition of World MS Day. She reflects on the importance of raising global awareness for MS, the need for equitable care, and the evolving focus of research and treatment. Dr. Hess discusses underrecognized symptoms like fatigue and cognitive dysfunction, and emphasizes the value of the upcoming diagnostic criteria update in enabling earlier intervention. She highlights key research priorities—including progressive MS, symptom management, and remyelination—and speaks to the importance of holistic, lifestyle-informed care. Finally, she shares advice for clinicians on how to communicate a new MS diagnosis with empathy, clarity, and empowerment.

Looking for more multiple sclerosis discussion? Check out the NeurologyLive® Multiple sclerosis clinical focus page.

Episode Breakdown:

• 1:00 – Significance of World MS Day and the importance of global MS awareness
• 2:05– Commonly recognized vs overlooked MS symptoms in patient care
• 3:10 – Transitioning to updated MS diagnostic criteria and the need for global provider education
• 4:15 – Neurology News Minute
• 6:30 – Research priorities: progressive MS, symptom management, and remyelination strategies
• 7:35 – The role of lifestyle, risk factor control, and holistic care in MS management
• 8:50 – Communicating MS diagnosis with empathy, support, and resource guidance

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves First Autoinjector Form of DHE for Acute Migraine and Cluster Headache
• FDA Clears Lumipulse Plasma Ratio as First Blood Test for Diagnosing Alzheimer Disease
• Once-Daily Oral Pill for Obstructive Sleep Apnea Shows Promising Phase 3 Results, Paving Way for FDA Submission

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Refining TSC Care: Phenotyping, Clustering, and Clinical Impact," Ajay Gupta, MD, director of the Tuberous Sclerosis Program at Cleveland Clinic, discusses recently published research that used unsupervised clustering to group over 900 patients with tuberous sclerosis complex (TSC) into four clinically meaningful phenotypic clusters. He outlines the distinct traits of each cluster—ranging from tumor risk to cognitive impairment—and explains how variant-specific genetic data helped reinforce these categories. Gupta, who also serves as a professor of neurology at the Cleveland Clinic Lerner School of Medicine, also explores the clinical value of these findings for surveillance planning, early intervention, and future therapeutic trials. He emphasizes that while overlap between clusters exists, this approach lays essential groundwork for precision care and more targeted research in TSC.

Looking for more epilpesy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:00 – Study goals and the shift from genotype-to-phenotype toward phenotype-to-genotype mapping
• 2:40– Overview of the 4 main phenotypic clusters identified in the TSC population
• 8:05 – Genetic domain associations and their impact on clinical monitoring and treatment
• 11:50 – Neurology News Minute
• 14:45 – Understanding overlap between clusters and avoiding overprediction in clinical settings
• 17:00 – Implications for future surveillance strategies and precision candidate selection in TSC trials

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA AdComm Plans to Review Investigational Cell Therapy Deramiocel for DMD Cardiomyopathy
• Gene Therapy AAV-GAD Gains Regenerative Medicine Advanced Therapy Designation as Potential Parkinson Treatment
• Microbiome-Targeting Therapy MaaT033 Continues to Show Promise in Final Phase 1 Readout

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress," Elizabeth Head, PhD, professor in the department of Pathology and Laboratory Medicine at the University of California, Irvine, discussed the evolving intersection of Down syndrome and Alzheimer disease using updates from the Alzheimer Biomarker Consortium – Down Syndrome (ABC-DS). She detailed how outcome assessments have been refined to meet the unique cognitive profiles of individuals with Down syndrome and shared the progress in launching clinical trials that now include this historically excluded population. Head also addressed the challenges in distinguishing developmental delay from early dementia symptoms, the potential role of anti-amyloid therapies, and how non-pharmacological interventions like sleep apnea treatment may contribute to cognitive preservation. She emphasized the importance of equitable research participation, clinician education, and understanding patient priorities—like independence and respect—when supporting individuals with Down syndrome and their families.

Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page.

Episode Breakdown:

• 1:00 – Overview of the ABC-DS initiative and the growing inclusion of Down syndrome in Alzheimer research
• 2:00– Current state of clinical trials and progress in therapeutic development for this population
• 3:30 – Evolution of outcome assessments tailored for individuals with Down syndrome
• 5:40 – Challenges in distinguishing Down syndrome traits from signs of early dementia
• 7:40 – Clinician educations needs and improving access to specialized care
• 9:00 – Neurology News Minute
• 11:00 – Eligibility and considerations for anti-amyloid therapies in Down syndrome
• 13:35 – Research gaps, co-occurring conditions, and the importance of reaching underserved populations
• 16:40 – Top priorities from patients and families: independence, inclusion, and respect in care settings

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose
• FDA Grants Authorization to Epiminder’s Implantable Continuous EEG Monitor for Epilepsy Treatment
• FDA Approves FcRn Blocker Nipocalimab for Broad Forms of Generalized Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Sleep and Seizures: Emerging Insights From AAN 2025," Nancy Foldvary-Schaefer, DO, director of the Sleep Disorders Center at Cleveland Clinic, reflected on key sleep-related topics presented at this year’s AAN Annual Meeting. She highlighted the growing clinical interest in underrecognized conditions like idiopathic hypersomnia and narcolepsy, stressing the need for better awareness and earlier diagnosis. Foldvary-Schaefer also detailed the development of the Sleep by Cleveland Clinic mobile app, designed to improve screening for common sleep disorders with validated tools and real-time resources. Additionally, she discussed new findings on the prevalence of obstructive sleep apnea in adults with epilepsy, pointing to the importance of routine sleep screening in this population, regardless of seizure severity. Finally, she shared exploratory data on SSRI use and peri-ictal respiratory patterns in epilepsy, offering new perspectives on potential protective mechanisms tied to SUDEP risk.

Looking for more neuromuscular discussion? Check out the NeurologyLive® Sleep disorders clinical focus page.

Episode Breakdown:

• 1:00 – Key sleep topics discussed at AAN 2025 and the growing interest in hypersomnia
• 5:45 – Development and purpose of the SLEEP mobile app by Cleveland Clinic
• 10:35 – Findings on obstructive sleep apnea prevalence in adults with epilepsy
• 15:05 – Neurology News Minute
• 17:10 – The need for sleep disorder screening in epilepsy clinical trials
• 19:45 – Exploratory findings on SSRI use and respiratory patterns in patients with epilepsy

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Pre-Filled Syringe Administration for FcRn Modulator Efgartigimod
• FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine
• FDA Expands Diazepam Nasal Spray Indication to Treat Ages 2 to 5

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Training the Next Generation of Neurology Nurse Practitioners," Daniel Harrison, MD, neurointensivist and assistant professor of neurology at Boston Medical Center, discussed his role as a senior author on a paper focused on a national needs assessment survey of neurologic education in nurse practitioner (NP) programs. In the conversation, Harrison explained how the survey aimed to understand neurology education across NP programs and identify gaps in training for advanced practice providers. He highlighted key findings, including the importance of lesion localization and neuroradiology for NP postgraduate training. While basic neurology education is integrated into many NP programs, he emphasized the need for more hands-on clinical experiences in specialized areas like neurocritical care and neuro-oncology. He also discussed the critical shortage of preceptors for neurology rotations, which hinders clinical education. Looking ahead, Harrison shared his thoughts on the growing role of NPs in neurology, forecasting a substantial increase in their numbers over the next decade and its impact on both clinical care and education. He also acknowledged the contributions of his colleague, Kate Sweeter, NP, who played a key role in the research, highlighting the importance of NPs in clinical care and academic advancements in neurology.

Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

• 1:00 – Overview of the national needs assessment survey 
• 3:45 – Importance of lesion localization and neuroradiology for NP postgraduate training
• 6:05 – The role of neuropathology in neurology education for nurse practitioners
• 8:05 – Challenges with clinical rotation preceptors and the shortage in neurology
• 9:40 – Neurology News Minute
• 12:10 – The role of NP programs in providing clinical experience
• 14:55 – Variability and lack of standardization in NP neurology education
• 18:05 – Evolving duties and responsibilities of NPs over the coming years
• 19:35 – Closing thoughts, acknowledging the contributions of Kate Sweeter, NP, and the value of NPs in neurology

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts Regulatory Submission for BTK Inhibitor Tolebrutinib for Non-Relapsing Secondary Progressive MS
• FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
• Genentech Reports High-Dose Ocrelizumab Fails to Show Additional Benefit in Relapsing MS

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we cover the recent approval of Supernus Pharmaceuticals' agent SPN-830, marketed as Onapgo, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson disease (PD). SPN-830, which has been available in Europe for several years, was approved based on data from the TOLEDO study (NCT02006121), a randomized, double-blind study in which treatment with the device was associated with a difference of –1.89 hours per day of OFF time for patients with PD in comparison with placebo. To gain greater insights on how this approval impacts the clinical and patient communities, NeurologyLive® sat down with movement disorder experts Stuart Isaacson, MD, director of the Parkinson’s disease and movement disorders center of Boca Raton, and Rajesh Pahwa, MD, the Laverne and Joyce Rider professor of neurology at the University of Kansas Medical Center. The duo discussed the significance of the approval, considerations for patient selection with the treatment, as well as the studies supporting its safety and efficacy. In addition, the pair provided context on how this approval, along with other recent approvals in PD, speak to the progress the clinical and research community has made over the years.


For more of NeurologyLive's coverage of SPN-830 for Parkinson disease, head here: FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment
Episode Breakdown:

• 1:05 – Significance of SPN-830's approval and impact on PD community
• 3:10 – Considerations for treatment selection with SPN-830, conversations with families
• 5:50 – Neurology News Minute
• 7:50 – TOLEDO study, supportive efficacy and safety data for SPN-830
• 11:45 – Expanding PD treatment options and overviewing recent progress in research

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Vutrisiran for ATTR-CM, Expanding Indication in Amyloidosis
• FDA Accepts Regulatory Submission for BTK Inhibitor Tolebrutinib for Non-Relapsing Secondary Progressive MS
• Simufilam Fails to Meet Key End Points in Phase 3 Alzheimer Disease Trial

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Advancing Neuromuscular Care and Research," former FDA commissioner Robert Califf, MD, explored the urgent need for sustained NIH funding to advance basic and translational research, including gene editing, assistive devices, and the integration of artificial intelligence. He emphasized the collaborative spirit of the neuromuscular community, where shared technologies and insights can address multiple disorders. The conversation, which took place at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific conference, highlighted critical challenges, such as clinician shortages, healthcare system strain, and the need for post-market learning to manage uncertainties with emerging therapies like gene therapy. Additionally, he called for innovative funding solutions to address the high costs of treatment, ensure equitable access, and maintain progress in neuromuscular care while fostering long-term health equity.

Looking for more epilepsy discussion? Check out the NeurologyLive® neuromuscular clinical focus page.

Episode Breakdown:

• 1:05 – Funding priorities for neuromuscular research and NIH support
• 1:55 – Role of gene editing, assistive devices, and AI in care
• 4:50 – Collaboration and togetherness of the neuromuscular community
• 6:35 – Considerations as new therapeutics emerge for neuromuscular disorders
• 8:05 – Funding solutions for equitable care

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we cover the recent approval of Genentech's tenecteplase, marketed as TNKase, as a new treatment for adults with acute ischemic stroke (AIS). The thrombolytic medicine is an intravenous tissue plasminogen activator that is clot-dissolving, administered as a single 5-second intravenous bolus. Tenecteplase is only the second such approval for this indication, following the 2015 approval of alteplase (Activase; Genentech); however, tenecteplase is considered faster and more simply administered than alteplase. To better understand the implications of this approval, NeurologyLive sat down with stroke expert Bijoy Menon, MD, MSc, FRCPC, a professor of neurology at the University of Calgary. In the interview, Menon talked about the downstream impacts of having another approved therapy, how tenecteplase differs from other thrombolytic agents, and the efficacy and safety that supported its approval. Furthermore, he provided commentary on how the approval continues to chip away toward the idea of precision medicine and personalizing treatments for patients with AIS. 


For more of NeurologyLive's coverage of sodium oxybate's (Lumryz) expanded indication, head here: FDA Approves Tenecteplase for Acute Ischemic Stroke
Episode Breakdown:

• 1:40 – Immediate reaction and significance of tenecteplase approval
• 5:30 – Safety considerations and administration when prescribing tenecteplase
• 10:20 – Supportive efficacy and safety, phase 3 AcT trial, and other supplementary studies
• 14:50 – Advancing precision medicine, treatment personalization with new approval

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, Sonal Bhatia, MD, FACNS, epilepsy expert and director of the pediatric epilepsy monitoring unit (EMU) at the Medical University of South Carolina, discussed Purple Day, celebrated on March 25th, and the importance of raising awareness for patients with epilepsy, a common condition affecting one in 26 individuals. She discussed the stigma faced by patients with epilepsy, especially in parts of the world outside the United States. Bhatia also discussed some of the recent advances in epilepsy care in the past decade, highlighting areas like improved surgical approaches, dietary therapies, and the potential of gene therapy for various disorders. In addition, she discussed changes in elderly epilepsy care, as well as the importance of transitioning care from pediatrics to adults and the need for a longitudinal model of care. Furthermore, she spoke on epilepsy monitoring units, the challenges institutions face, and the critical need for EEG technology and for more EEG technologists and nursing school graduates. 

Looking for more epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:10 – Significance of Purple Day, raising awareness on epilepsy stigma
• 5:00 – Advances in epilepsy care, including availability of more anti-seizure medications and genetic insights
• 8:45 – Neurology News Minute
• 11:10 – Challenges in elderly epilepsy care and the need for more standardized transition models from pediatrics to adulthood
• 15:20 – Optimizing epilepsy monitoring units and dealing with staff and equipment shortages
• 20:50 – Closing thoughts

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Medtronic’s Adaptive Deep Brain Stimulation for Parkinson Disease
• FDA Approves Tenecteplase for Acute Ischemic Stroke
• FDA Approves Expanded Use of Eculizumab for Pediatric Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, Julie Flygare, JD, president and chief executive officer of Project Sleep, shared her personal and professional insights into the critical role of social connections for patients living with narcolepsy and idiopathic hypersomnia. Drawing from her journey with narcolepsy, Flygare highlighted the challenges of isolation at diagnosis and the transformative power of peer support and advocacy. She delved into survey findings that underscore the rarity of social connections among patients and their impact on adjustment and well-being. Additionally, Flygare offered actionable recommendations for clinicians to integrate social support into practice, emphasizing the value of patient advocacy organizations and fostering meaningful connections. Above all, her inspiring perspective shed light on the intersection of community, research, and clinical care in sleep health.

Looking for more narcolepsy discussion? Check out the NeurologyLive® Narcolepsy clinical focus page.

Episode Breakdown:

• 1:00 – Challenges and importance of social connections
• 5:45 – Building a thriving community and research impact
• 7:30 – Insights from patient surveys on social support
• 10:30 – Neurology News Minute
• 12:25 – Recommendations for clinicians on social support

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas in Adults and Children
• FDA Approves Tablet Formulation of Risdiplam for Spinal Muscular Atrophy
• Solid Reports Positive Data for SGT-003 Gene Therapy in Phase 1/2 Trial of Duchenne

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, Veronique Miron, PhD, The John David Eaton Chair in Multiple Sclerosis at the University of Toronto, gave a clinical overview of the 2025 ACTRIMS Forum, which is held February 27-March 1, in West Palm Beach, Florida. Miron, an expert in the field, spoke on the reasons behind this year's theme of "Making Connections," as well as some of the most notable and innovative sessions attending clinicians should keep their eyes on. Additionally, she spoke on how the curriculum at this year's meeting aligns with the most recent MS McDonald Diagnostic Criteria that was presented at ECTRIMS 2024. Miron also spoke on the different seminars that cover drug development, innovative new treatment approaches, and Bruton Tyrosine Kinase (BTK) inhibitors. Furthermore, she provided commentary on how this year's meeting differs from previous iterations of ACTRIMS, highlighting some of the changes to the agenda and the advances in MS research.

Looking for more multiple sclerosis discussion? Check out the NeurologyLive® Multiple sclerosis clinical focus page.

Episode Breakdown:

• 1:10 – Reasons behind "Making Connections" theme 
• 2:50 – Overviewing key unique sessions and forums from the meeting
• 5:10 – Aligning curriculum with 2024 MS McDonald Criteria
• 7:00 – Neurology News Minute
• 9:00 – Drug development topics from ACTRIMS 2025
• 12:20 – Differences between ACTRIMS 2025 vs ACTRIMS 2024

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment
• FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
• FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, epilepsy expert Depobam Samanta, MD, MS, FAAP, FAES, sat down to discuss a recently published guidance paper from members of the Pediatric Epilepsy Research Consortium that provides recommendations for neuromodulation approaches to treat Lennox-Gastaut syndrome (LGS). Samanta, medical director of the Arkansas Children's Comprehensive Epilepsy Program, gave a clinical overview of the paper, highlighting the various neuromodulatory devices and their use, and the ways to improve treatment selection and personalization. Additionally, he talked about some of the potential complications with these devices as well as initiation and titration strategies for easy initiation. Furthermore, he spoke about ways to take neuromodulation to the next level, giving insight on creative trial designs, overcoming sham-controlled studies, and the necessary research to expand these approaches. 

Looking for more epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:05 – Overview of the published guidance and reasons behind the paper 
• 5:15 – Patient selection for neuromodulation and tailoring treatments by patient and preference
• 8:25 – Overcoming complications with neuromodulation devices 
• 11:25 – Multidisciplinary team necessary for successful implementation of neuromodulation
• 13:15 – Neurology News Minute
• 15:15 – Initiation and titration strategies for vagus nerve stimulation, deep brain stimulation, and resective surgery
• 18:30 – Next steps in research and expanding neuromodulation for patients with LGS
• 21:10 – Finding creative trial designs to test neuromodulation devices, combination approaches

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts BLA for Subcutaneous Autoinjector Formulation of Lecanemab
• Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease
• Real-World Study Highlights Positive Treatment Benefits of Tofersen on ALS Disease Progression, Function

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, Russ Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the company's SAAmplify-aSYN biomarker test, a first-in-class qualitative laboratory developed test and the only seed amplification assay available to aid in the diagnosis of synucleinopathies such as Parkinson disease (PD) and multiple system atrophy (MSA). Lebovitz provided insight on the new technology and its remarkable accuracy in identifying underling a-synuclein pathology using fluorescence changes. He gave a complete overview of the notable study published in The Lancet Neurology that further tested and validated the assay among a heterogenous group of synucleinopathies. Furthermore, he provided clinical context on the feasibility of the assay, the potential for clinical use, and the continued validation needed. 

Looking for more movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

Episode Breakdown:

• 1:05 – Overviewing mechanistic function of SAAmplify-aSYN biomarker test, its purpose, and how it came about
• 7:50 – Results from the published study; ways the fluorescence-based amplification method could distinguish MSA from PD and Lewy body dementia
• 16:25 – Neurology News Minute
• 18:30 – Therapeutic feasibility of the assay in clinical settings and the next steps in validation

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Axsome to Submit NDA for AXS-05 in Alzheimer Agitation Following Positive Phase 3 Trials
• FDA Clears IND for Trial Assessing Gene Therapy SGT-212 in Friedreich Ataxia
• FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this special episode, we’ve compiled some of the most compelling conversations from Mind Moments podcast episodes throughout 2024. These discussions spotlight groundbreaking research and advancements in neurology that are propelling the field forward. The NeurologyLive team also explored the impact of several newly FDA-approved therapies, offering clinicians valuable insights into what these treatments mean for patient care and their practical use in the clinic. Featured in this week’s episode, in order of appearance, are:

• Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, who gave an overview on the new 2024 McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-125-understanding-major-changes-new-mcdonald-criteria-multiple-sclerosis
• Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, on the changing and exciting advances in Alzheimer disease therapeutics, as well as the discontinuation of aducanumab, the first approved antiamyloid therapy. 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-113-lessons-learned-alzheimer-drug-development
• Andy Berkowski, MD, PhD, vice chair of the American Academy of Sleep Medicine's Practice Guidelines Task Force, discusses the newly revised guidelines for restless legs syndrome, including the latest updates in literature and changes to clinical care. 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-129-implications-2024-aasm-guidelines-restless-legs-syndrome
• Sameea Husain-Wilson, DO, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease.
  • Check out the full episode here: https://www.neurologylive.com/view/episode-119-utilizing-the-syn-one-test-to-diagnose-parkinson-disease
• Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke at the 2024 American Epilepsy Society Annual Meeting on cell therapy approaches for epilepsy, the challenges the clinical community faces, and the outlook for the future. 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-130-promise-behind-cell-therapy-approaches-epilepsy
• Lawrence Robinson, MD, a senior scientist at Sunnybrook Research Institute, gives insight on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners, and the major differences in how this generation of medical students learn relative to previous ones. 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-127-adapting-neuromuscular-electrodiagnostic-medicine-education-modern-learners

Want more Mind Moments episodes? Click here for all of NeurologyLive®'s podcast episodes.

Episode Breakdown:

• 1:05 – Ontaneda on the incorporation of new biomarkers into the 2024 McDonald Criteria for multiple sclerosis.
• 7:35 – Kremer on the lessons learned from drug development, including antiamyloid treatments, and initial reaction to the discontinuation of aducanumab for AD. 
• 10:30 – Berkowski on the outlook of treating and preventing restless legs syndrome going forward using the newly updated American Academy of Sleep Medicine treatment guidelines. 
• 13:10 – Husain-Wilson on the function of the Syn-One test for Parkinson disease, its applicability, and how it may distinguish patients with PD from other synucleinopathies.
• 18:40 – Parker on the promise and thought process behind stem cell approaches for drug-resistant epilepsy, including the different types of cell methods being tested. 
• 21:45 – Robinson on the distinct differences in learning styles based on generation, the importance of adaptive teaching, and the new approaches educators in neuromuscular and electrodiagnostic medicine can take. 

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke about the emerging commotion around cell therapies as a way to treat patients with epilepsy. The discussion, which took place at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California, covers the thought process behind this approach and why it may hold greater advantages over other traditional surgeries that result in detrimental cognitive effects. Parker, director of the Device-Based Neuroelectronics Lab, spoke on the different types of cell therapies currently in development, the limitations and challenges associated with these medications, and the need to create innovative trials to appropriately test them. Furthermore, Parker spoke on the therapeutic pipeline of cell therapies for epilepsy, including his experience leading a study site for a first-in-human trial of an investigational agent NRTX-1001, a product derived from human pluripotent stem cells.

Looking for more epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 1:00 – Idea behind cell therapy to treat epilepsy
• 4:05 – Current state of stem cell therapies for neurological disorders, focusing on Parkinson disease, stroke, and epilepsy
• 8:05 – NTE001 study of NRTX-1001, an investigational human embryonic stem cell product
• 11:45 – Neurology News Minute
• 13:50 – Unanswered questions and safety concerns with cell therapies; challenges with clinical trial design and the need for more innovative trials
• 17:35 – Misconceptions or gaps in understanding about cell therapies for epilepsy
• 20:05 – Unique challenges and potential of stem cell therapies for epilepsy, particularly in younger patients; patient motivation and hope

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Anavex Submits Marketing Authorization Application for Blarcamesine in Alzheimer Disease in the EU
• Testing Begins for RELIEV-CM2 Study of ShiraTronics Neuromodulation Device in Chronic Migraine
• STK-001 Gains FDA Breakthrough Designation as Potential Disease-Modifying Treatment for Dravet Syndrome

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.